All Stories

  1. Measuring what matters! The role of AAV-PRO in patient-centered care for EGPA: insights from the study by Delvino et al.
  2. Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
  3. From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey
  4. Comments on the article by Goldman et al.
  5. Ethical challenges and regulatory pathways for artificial intelligence in rheumatology
  6. Correction: Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
  7. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
  8. Unveiling Cancer Risk in ANCA-Associated Vasculitis: Result from the Turkish Vasculitis Study  Group (TRVaS)
  9. Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists. Second reply
  10. Adapting HUVAC Vasculitis Registry to a Country-wide online registry system: Turkish Vasculitis Study Group Prospective Database, TRVaS
  11. Costovertebral and costotransverse joint involvement in spondyloarthritis
  12. Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply
  13. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy—findings from the TReasure database: a 5-year follow-up study
  14. AI am a rheumatologist: a practical primer to large language models for rheumatologists
  15. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
  16. Comparison of lupus nephritis and non-lupus nephritides in patients with systemic lupus erythematosus
  17. Comparison of demographic, clinic and radiological features of patients with axial spondyloarthritis accompanying familial Mediterranean fever to patients with each condition alone
  18. Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database
  19. Autoinflammation in psoriatic arthritis: time to better define the multifaceted enemy
  20. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis
  21. Predicting the response to bDMARD treatment in RA: Then what?
  22. Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
  23. Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study
  24. Can we predict transition from psoriasis to psoriatic arthritis?
  25. The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results
  26. Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry
  27. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data
  28. The frequency of Achilles and plantar calcaneal spurs in gout patients
  29. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
  30. c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature
  31. Iliac artery aneurysm in Behçet’s syndrome: collaborative management is essential
  32. Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020
  33. Successful treatment of penile Mondor’s disease with infliximab in a patient with Behçet’s disease
  34. Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis
  35. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience
  36. PILE: a candidate prognostic score in cancer patients treated with immunotherapy
  37. Proposal of a new nomenclature for the underlying pathogenetic mechanism of severe Coronavirus Disease-19: “Inflammatory Thrombosis with Immune Endotheliitis—ITIE”
  38. Mediastinal mass in a patient with rheumatoid arthritis: lymphoid cystic thymic hyperplasia
  39. Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center
  40. Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?
  41. Treatment modalities in psoriatic arthritis
  42. Geoepidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients’ data
  43. Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study
  44. Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis
  45. Comparison of Diagnostic Subgroup Survivals of Patients Who Admitted for Fever of Unknown Etiology Evaluation: Long-term Results of Single-centre, Prospective Study
  46. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
  47. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia
  48. Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
  49. Correction to: Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study
  50. Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study
  51. Some concerns from Turkey
  52. Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
  53. Blood group ‘A’ may have a possible modifier effect on familial Mediterranean fever and blood group ‘0’ may be associated with colchicine resistance
  54. Aspergillus Pneumonia in a Patient With Adult-Onset Still Disease Successfully Treated With Anakinra
  55. Familial Mediterranean fever: New insights into cancer immunoprevention?
  56. Increased psoriasis frequency in patients with familial Mediterranean fever
  57. The association of various social capital indicators and physical activity participation among Turkish adolescents
  58. Poor outcomes among elderly patients hospitalized for influenza-like illness
  59. Increased cancer risk in patients with periodontitis
  60. Comparing polyarteritis nodosa in children and adults: a single center study
  61. Amniotic Membrane Transplantation for Spontaneous Corneal Perforation in a Case Of Rheumatoid Arthritis
  62. Behçet Disease With Vascular Involvement